Cyril H. Benes

31.0k citations

123 papers · 10.9k indexed · 4 hit papers · h-index 49

Molecular Biology top 0.5%
Oncology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 0.5%
Computational Theory and Mathematics top 0.5%

Co-authors: Patricia Greninger Ultan McDermott Daniel A. Haber Mathew J. Garnett Jeffrey A. Engelman Sridhar Ramaswamy Lee Zou Michael R. Stratton
Topics: Cancer-related Molecular Pathways (14 papers)Cancer therapeutics and mechanisms (14 papers)DNA Repair Mechanisms (13 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Germany

In The Last Decade

Cyril H. Benes

120 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

2012 2.6k citations Patricia Greninger, Cyril H. Benes et al. profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Cyril H. Benes, Lecia V. Sequist et al. profile →
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

2015 376 citations Cyril H. Benes, Lee Zou et al. profile →

Peers

Countries citing papers authored by Cyril H. Benes

Since Specialization

Citations

This map shows the geographic impact of Cyril H. Benes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyril H. Benes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyril H. Benes more than expected).

Fields of papers citing papers by Cyril H. Benes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyril H. Benes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyril H. Benes. The network helps show where Cyril H. Benes may publish in the future.

Co-authorship network of co-authors of Cyril H. Benes

This figure shows the co-authorship network connecting the top 25 collaborators of Cyril H. Benes. A scholar is included among the top collaborators of Cyril H. Benes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyril H. Benes. Cyril H. Benes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models 2022 ·PNAS Nexus ·Sheeba Jacob,(unknown),Jinyang Cai,Konstantinos V. Floros,(unknown),(unknown),(unknown),Mohammad A. Alzubi,Charles T. Jakubik,(unknown),Madhavi Puchalapalli,(unknown),Mikhail G. Dozmorov,Sosipatros A. Boikos,Bin Hu,J. Chuck Harrell,Cyril H. Benes,Jennifer E. Koblinski,Carlotta Costa,Anthony C. Faber	6
2	Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma 2021 ·Molecular Cancer Therapeutics ·Daniel A.R. Heisey,Sheeba Jacob,Timothy L. Lochmann,Richard Kurupi,(unknown),(unknown),(unknown),(unknown),Jennifer E. Koblinski,Mikhail G. Dozmorov,Sosipatros A. Boikos,Cyril H. Benes,Anthony C. Faber	11
3	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors 2018 ·Cancer Research ·(unknown),Marta Baro,(unknown),Azeet Narayan,Wei Cui,Patricia Greninger,Regina K. Egan,Abhijit A. Patel,Cyril H. Benes,W. Mark Saltzman,Joseph N. Contessa	55
4	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity 2018 ·Clinical Cancer Research ·Daniel A.R. Heisey,Timothy L. Lochmann,Konstantinos V. Floros,(unknown),Krista M. Powell,Sheeba Jacob,(unknown),(unknown),Giovanna T. Stein,(unknown),Steven C. Smith,Cyril H. Benes,Joel Johansson,Andrew J. Souers,Sosipatros A. Boikos,Anthony C. Faber	22
5	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 2018 ·Clinical Cancer Research ·Anahita Dastur,(unknown),Carlotta Costa,(unknown),August Williams,Joseph McClanaghan,Max Greenberg,Justine E. Roderick,Neha U. Patel,(unknown),Ultan McDermott,Mathew J. Garnett,Jorge A. Almenara,Steven Grant,Kathryn Rizzo,Jeffrey A. Engelman,Michelle A. Kelliher,Anthony C. Faber,Cyril H. Benes	16
6	Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer 2017 ·Cancer Research ·Luz García‐Alonso,Francesco Iorio,Angela Matchan,Nuno A. Fonseca,Patricia Jaaks,Gareth Peat,Miguel Pignatelli,(unknown),Cyril H. Benes,Ian Dunham,Graham R. Bignell,Simon S. McDade,Mathew J. Garnett,Julio Sáez-Rodríguez	107
7	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression 2017 ·Clinical Cancer Research ·Timothy L. Lochmann,Konstantinos V. Floros,Mitra Naseri,Krista M. Powell,(unknown),Ryan J. March,Giovanna T. Stein,Patricia Greninger,(unknown),Laura R. Saunders,Scott J. Dylla,Carlotta Costa,Sosipatros A. Boikos,Joel Johansson,Andrew J. Souers,Geoffrey W. Krystal,Hisashi Harada,Cyril H. Benes,Anthony C. Faber	93
8	APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition 2017 ·Cancer Research ·Rémi Buisson,Michael S. Lawrence,Cyril H. Benes,Lee Zou	95
9	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics 2017 ·Molecular Cancer Therapeutics ·S.W. Ember,Que T. Lambert,Norbert Berndt,Steven Gunawan,Muhammad Ayaz,Marilena Tauro,J. Zhu,Paula J. Cranfill,Patricia Greninger,Conor C. Lynch,Cyril H. Benes,Harshani R. Lawrence,Gary W. Reuther,Nicholas J. Lawrence,E. Schönbrunn	41
10	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway 2017 ·Cancer Research ·(unknown),Jing Han,Lynnette Marcar,Joshua C. Black,Qi Liu,Xiangyong Li,Kshithija Nagulapalli,Lecia V. Sequist,Raymond H. Mak,Cyril H. Benes,Theodore S. Hong,Kristin Gurtner,Mechthild Krause,Michaël Baumann,Jing X. Kang,Johnathan R. Whetstine,Henning Willers	77
11	Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma 2017 ·Cancer Research ·Yan Liu,Yuyang Li,Xiaoen Wang,Feiyang Liu,Peng Gao,Max M. Quinn,Fei Li,Ashley A. Merlino,Cyril H. Benes,Qingsong Liu,Nathanael S. Gray,Kwok‐Kin Wong	25
12	N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation 2016 ·Molecular Cancer Therapeutics ·Min Wu,Jinyan Huang,Jianming Zhang,Cyril H. Benes,Bo Jiao,Ruibao Ren	14
13	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers 2015 ·Molecular Cancer Research ·Qi Liu,Meng Wang,(unknown),(unknown),Jing Han,Beow Y. Yeap,Theodore S. Hong,Jeff Settleman,Cyril H. Benes,Kathryn D. Held,Jason A. Efstathiou,Henning Willers	29
14	Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis 2015 ·Cancer Discovery ·Capucine Van Rechem,Joshua C. Black,Myriam Boukhali,Martin J. Aryee,S. Gräslund,Wilhelm Haas,Cyril H. Benes,Johnathan R. Whetstine	51
15	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer 2014 ·Clinical Cancer Research ·Brinda Alagesan,Gianmarco Contino,Alexander R. Guimarães,Ryan B. Corcoran,Vikram Deshpande,Gregory R. Wojtkiewicz,Aram F. Hezel,Kwok‐Kin Wong,Massimo Loda,Ralph Weissleder,Cyril H. Benes,Jeffrey A. Engelman,Nabeel Bardeesy	103
16	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibitionbreakdown → 2013 ·Cancer Discovery ·Alexandre Puissant,Stacey M. Frumm,Gabriela Alexe,Christopher F. Bassil,Jun Qi,Yvan H. Chanthery,Erin A. Nekritz,Rhamy Zeid,W. Clay Gustafson,Patricia Greninger,Matthew J. Garnett,Ultan McDermott,Cyril H. Benes,Andrew L. Kung,William A. Weiss,James E. Bradner,Kimberly Stegmaier	457
17	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent 2012 ·Cancer Discovery ·Jing Ni,Qingsong Liu,Shaozhen Xie,Coby B. Carlson,Thanh Von,Kurt Vogel,(unknown),Cyril H. Benes,Michael J. Eck,Thomas G. Roberts,Nathanael S. Gray,Jean J. Zhao	125
18	Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma 2012 ·Cancer Discovery ·Lei He,Kristine Torres‐Lockhart,Nicole Forster,Saranya Ramakrishnan,Patricia Greninger,Mathew J. Garnett,Ultan McDermott,S. Michael Rothenberg,Cyril H. Benes,Leif W. Ellisen	54
19	STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis 2011 ·Cancer Research ·Ryan B. Corcoran,Gianmarco Contino,Vikram Deshpande,Alexandros Tzatsos,Claudius Conrad,Cyril H. Benes,David T. Levy,Jeffrey Settleman,Jeffrey A. Engelman,Nabeel Bardeesy	334
20	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks 2011 ·Cancer Research ·Meng Wang,(unknown),David M. Sander,Liliana Gheorghiu,Akash Nanda,Cyril H. Benes,Malte Kriegs,Mechthild Krause,Ekkehard Dikomey,Michaël Baumann,Jochen Dahm‐Daphi,Jeffrey Settleman,Henning Willers	96

About Cyril H. Benes

Cyril H. Benes is a scholar working on Oncology, Cancer Research and Molecular Biology, having authored 123 papers that have together received 10.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (14 papers), Cancer therapeutics and mechanisms (14 papers) and DNA Repair Mechanisms (13 papers). The work is most often cited by research in Cancer Research (2.5k citations), Oncology (4.0k citations) and Molecular Biology (7.4k citations). Cyril H. Benes has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Patricia Greninger, Ultan McDermott, Daniel A. Haber, Mathew J. Garnett, Jeffrey A. Engelman, Sridhar Ramaswamy, Lee Zou, Michael R. Stratton, Howard Lightfoot and Wanjuan Yang. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact